Form 8-K - Current report:
SEC Accession No. 0001213900-24-097777
Filing Date
2024-11-14
Accepted
2024-11-14 06:45:34
Documents
14
Period of Report
2024-11-14
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0221192-8k_biomx.htm   iXBRL 8-K 23653
2 PRESS RELEASE DATED NOVEMBER 14, 2024 ea022119201ex99-1_biomx.htm EX-99.1 76263
  Complete submission text file 0001213900-24-097777.txt   285259

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE phge-20241114.xsd EX-101.SCH 3006
4 XBRL LABEL FILE phge-20241114_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE phge-20241114_pre.xml EX-101.PRE 22353
16 EXTRACTED XBRL INSTANCE DOCUMENT ea0221192-8k_biomx_htm.xml XML 3647
Mailing Address 22 EINSTEIN ST. FLOOR 4 NESS ZIONA L3 7414003
Business Address 22 EINSTEIN ST. FLOOR 4 NESS ZIONA L3 7414003 972 723942377
BiomX Inc. (Filer) CIK: 0001739174 (see all company filings)

EIN.: 823364020 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38762 | Film No.: 241457006
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)